Investors & Media

ARS Pharma is dedicated to empowering at-risk patients and their caregivers to better protect patients against allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU and UK and 优敏速® in China), an epinephrine nasal spray approved in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis.